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Abstract: We previously developed a transmission dynamic model of Neisseria meningitidis 
serogroup A (NmA) with the aim of forecasting the relative benefits of different immunisation strat-
egies with MenAfriVac. Our findings suggested that the most effective strategy in maintaining dis-
ease control was the introduction of MenAfriVac into the Expanded Programme on Immunisation 
(EPI). This strategy is currently being followed by the countries of the meningitis belt. Since then, 
the persistence of vaccine-induced antibodies has been further studied and new data suggest that 
immune response is influenced by the age at vaccination. Here, we aim to investigate the influence 
of both the duration and age-specificity of vaccine-induced protection on our model predictions and 
explore how the optimal vaccination strategy may change in the long-term. We adapted our previ-
ous model and considered plausible alternative immunization strategies, including the addition of 
a booster dose to the current schedule, as well as the routine vaccination of school-aged children for 
a range of different assumptions regarding the duration of protection. To allow for a comparison 
between the different strategies, we use several metrics, including the median age of infection, the 
number of people needed to vaccinate (NNV) to prevent one case, the age distribution of cases for 
each strategy, as well as the time it takes for the number of cases to start increasing after the honey-
moon period (resurgence). None of the strategies explored in this work is superior in all respects. 
This is especially true when vaccine-induced protection is the same regardless of the age at vaccina-
tion. Uncertainty in the duration of protection is important. For duration of protection lasting for 
an average of 18 years or longer, the model predicts elimination of NmA cases. Assuming that vac-
cine protection is more durable for individuals vaccinated after the age of 5 years, routine immun-
ization of older children would be more efficient in reducing disease incidence and would also re-
sult in a fewer number of doses necessary to prevent one case. Assuming that elimination does not 
occur, adding a booster dose is likely to lead to prevent most cases but the caveat will be a more 
costly intervention. These results can be used to understand important sources of uncertainty 
around MenAfriVac and support decisions by policymakers.  
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1. Introduction 
Countries in the meningitis belt of sub-Saharan Africa have been repeatedly devas-
tated by meningitis epidemics since the early 1900s. Primarily, these epidemics are caused 
by the bacterium Neisseria meningitidis and a number of circulating meningococcal 
serogroups are responsible for causing disease in the meningitis belt [1]. Until 2010, the 
predominant serogroup responsible for frequent epidemic cycles was N. meningitidis 
serogroup A (NmA) [2]. Since the introduction of a tailor made vaccine, MenAfriVac in 
2010, over 300 million 1–29 year olds have been vaccinated against NmA, resulting in a 
more than 99% decline in the number of confirmed group A cases in fully vaccinated pop-
ulations [3].  
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We previously developed a transmission dynamic model of NmA with the aim of 
forecasting the relative benefits of different immunisation strategies [4]. The model high-
lighted the importance of a long-term vaccination strategy following the introductory 
mass campaigns of 1–29 year olds. Of the long-term strategies we investigated, a combi-
nation strategy of routine immunisation within the Expanded Programme on Immunisa-
tion (EPI) together with a mini catch-up, targeting children born after the introductory 
campaign, was the most effective. After reviewing the model findings and additional com-
prehensive information from clinical trials, the World Health Organisation’s recommen-
dation for the countries of the African meningitis belt is to introduce MenAfriVac into 
routine immunisation programmes within 5 years after completion of the mass cam-
paigns. The vaccine regimen is a 1-dose schedule given at 9–18 months of age. At the time 
of introduction into EPI, it is recommended that countries should also include a one-time 
catch-up campaign to immunise those born since the introductory campaigns [5].  
One of the key assumptions in our previous work was that the duration of vaccine 
induced protection is the same for all ages. Due to limited data at the time, we assumed 
that MenAfriVac offered protection for an average of 10 years. Since then, several studies 
have investigated the persistence of vaccine-induced antibodies and the influence of age 
at vaccination. These studies provide empirical evidence on the duration of the immune 
response to MenAfriVac, which may be used as a proxy to the duration of protection. 
Correlates of protection for meningococcal disease are based upon serum bactericidal ac-
tivity (SBA) [6]. The studies by White et al. [7] and Yaro et al. [8] suggest that vaccine 
protection is age-dependent and lasts longer for individuals targeted after the age of 2 
years or 5 years, respectively. These new studies were consistent in suggesting that the 
duration may be age-specific, but inconsistent in their estimates of the duration. 
The aim of this paper is to investigate the influence of both the duration and age-
specificity of vaccine-induced protection on our model predictions and explore how the 
optimal vaccination strategy may change in the long-term. More specifically, we consider 
four scenarios that could be plausible alternative strategies to the current. 
2. Materials and Methods 
2.1. Model Structure 
Details of the model structure have been previously published [4]. In brief, it is a 
compartmental model that divides the population into: susceptible state, carrier of NmA, 
disease due to NmA, and recovered and immune, with each of these states replicated for 
vaccinated and unvaccinated.  
In a modification for this paper, instead of having broad age groups, we now divided 
the population into annual age cohorts. A model modification was also necessary in order 
to simulate an age-dependent duration of protection. We added four new compartments 
to the previous model. These four states represent the susceptible, carriers, diseased, and 
recovered/immune who receive vaccination before the age of five years. A table with all 
of the compartments and their descriptions can be found in Appendix A, together with a 
flow diagram of the model. 
2.2. Model Parameters 
Demographic data for Chad were used to estimate parameters for the model. Epi-
demics of NmA in Chad in the pre-vaccine era occurred every 8–12 years, which is repre-
sentative of the epidemiology of NmA in the African meningitis belt [9]. The introduction 
of MenAfriVac in that country was completed in two phases during 2011 and 2012 [10]. 
In the model, because there is no geographic sub-division, we assume that 50% of the 
target population were vaccinated in 2011 while the remaining 50% received the vaccine 
in 2012.  
We assumed that the coverage in Chad for routine immunisation of infants starts at 
75% in 2017 and continues with annual increments of 1% until it reaches 90%. It is then 
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assumed to stay constant for the remaining years. There is no vaccine currently being ad-
ministered at 5 or 10 years of age. Hence, we explored the impact of vaccinations, assum-
ing a coverage of 80% at these ages. Other parameters were based on the available litera-
ture wherever possible, as previously described [4].  
To account for the uncertainty around the duration of protection, we ran each sce-
nario outlined below under the following four different assumptions: (1) an average of 5 
years duration of protection for all ages; (2) 10 years duration of protection for all ages; (3) 
20 years duration of protection for all ages; and (4) 5 years duration of protection for <5 
year olds and 10 years duration of protection for children at 5 years of age or older.  
2.3. Vaccination Strategies 
We considered a range of vaccination strategies (Table 1) that were elucidated 
through informal discussions with colleagues at WHO, PATH, and CDC to be of interest.  
Table 1. Vaccination strategies considered in the model. 
Strategy Introduction Catch-Up 
Campaign 






2017: 1–6 years 
old 2017–2060: at 12 months 
75% in 2017 and annual incre-
ments of 1% until it reaches 90% 
EPI@5y 
2011–2012: 1–29 
years old None 2017–2060: at 5 years 80% 
EPI@10y 2011–2012: 1–29 
years old 
None 2022–2060: at 10 years 80% 
Booster 2011–2012: 1–29 years old None 
2017–2060: at 12 months and 5 
years 
• 75% in 2017 and annual in-
crements of 1% until it reaches 
90% for 12 month olds 
• 80% for 5 year olds 
Switch 2011–2012: 1–29 
years old 
2017: 1–6 years 
old 
2017–2021: at 12 months 
2022–2026: at 12 months and 5 
years 
2027–2060: at 5 years 
• 75% in 2017 and annual in-
crements of 1% until it reaches 
90% for 12 month olds 
• 80% for 5 year olds 
2.4. Model Implementation 
The model is run for the time period 2010–2060 using a daily time step. For each 
model run, the number of cases by age is calculated per year. The average number of cases 
and the percentage of cases prevented by each of the strategies is calculated over 200 sim-
ulation runs per strategy. To account for the uncertainty due to the stochastic nature of 
the model, 95% confidence intervals were calculated using a student-t distribution as im-
plemented by the t-test function in R version 3.4.2 [11]. 
To allow for a comparison between the different strategies, we report the time to re-
surgence, median age of infection, and the age distribution of cases for each strategy. As 
time to resurgence, we define the year in which the number of cases exceeds the threshold 
of 1 case per 100,000 population following the preventive campaigns. The comparison of 
each metric is based on non-overlapping confidence intervals. Due to the large range from 
10 years to 20 years duration of protection for all ages, we also investigate the effect of all 
the intermediate years on the time to resurgence in a sensitivity analysis. As an additional 
measure of efficiency, we calculated the number of people needed to vaccinate (NNV) to 
prevent one case [12]. We define NNV as the total number of doses administered divided 
by the total number of cases prevented under each vaccination strategy over the time pe-
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riod under consideration. The total number of doses given for each scenario was calcu-
lated by multiplying the total number of people targeted with the assumed age-specific 
vaccine uptake. 
3. Results 
3.1. Baseline Scenario (10 Years Duration of Protection) 
The model results suggest that if the assumed duration of protection is 10 years for 
all ages, routine immunization aimed at schoolchildren is not better than routine immun-
ization of 1-year-old children. However, switching the age at vaccination from 12 months 
to 5 years is the single dose strategy with the lowest average number of cases predicted, 
albeit there is a 5-year period with two doses. The numerical results for the different strat-
egies are given in Appendix B. The strategy that leads to the largest number of cases 
averted is the Booster strategy with a 79.3% (CI: 78.7–79.8%) predicted overall reduction, 
relative to a 66.8% (66.2–67.4%) predicted reduction if the current strategy remains un-
changed until 2060, but the NNV is much higher (Table A2). 
3.2. Time to Resurgence 
The model predicts that when the assumed duration of protection is 12 years or 
shorter for all ages, a resurgence always follows the initial mass campaigns (Figure 1). The 
size of the peak as well as the year of resurgence both depend on the schedule and the 
duration of protection. The longer the duration of protection, the longer the honeymoon 
period is. No resurgence was seen in model runs (i.e., 100% of the 200 simulations result 
in elimination) when vaccine-induced protection was assumed to last for an average of 18 
years or longer. For an assumed duration of protection of 16 years for all ages, 69.5% of 
the simulation runs resulted in elimination after the mass campaigns. Summary statistics 
showing the year the disease incidence exceeds the threshold of one case per 100,000 pop-
ulation for duration of protection between 10 and 20 years can be seen in Table A3 in 
Appendix B. 




Figure 1. Average disease incidence across the different vaccination scenarios and across the different assumptions re-
garding the duration of vaccine-induced protection. Shaded areas represent the 95% confidence intervals. 
If we assume that duration of protection is 5 years regardless of the age at vaccina-
tion, the model predicts that the number of cases will start increasing only 10 years after 
the introduction of MenAfriVac, compared to ~17 years of honeymoon period when du-
ration of protection is 10 years. Earlier resurgence does not necessarily translate to a larger 
number of total cases (Figure 2).  
3.3. Burden of Disease  
Of the strategies considered, the Booster strategy resulted in the fewest cases across 
all different assumptions regarding the duration of protection (Figure 3, Table 2). Taking 
into consideration only the single-dose schedules, the model results suggest that if the 
duration of protection is assumed to be the same for everyone regardless of at what age 
they are targeted, routine immunization at 12 months of age (EPI@12m) is similar to rou-
tine immunization at older ages (EPI@5y and EPI@10y). There is considerable overlap in 
the results but strategy Switch is the strategy with the lowest average number of total 
cases predicted (Figure 3). However, assuming that vaccination of 1-year-old leads to a 
shorter duration of antibody persistence compared to vaccination at older ages, strategies 
EPI@5y and EPI@10y result in a lower number of predicted cases compared to the 
EPI@12m strategy.  




Figure 2. Total number of cases plotted against the year of resurgence across all scenarios and all 
assumptions regarding duration of protection and coverage. Each strategy is represented with a 
different colour and each assumption about the duration of protection is represented with a differ-
ent symbol shape. Note that 20 years duration of protection is not shown. Error bars show the 95% 
confidence interval. 
 
Figure 3. Box plot showing the median, interquartile range, and full range of the predicted total 
number of cases for different immunisation strategies in the time period 2010–2060 from 200 simu-
lation runs. 
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Table 2. Number of doses given, number of cases predicted and averted, and number of doses needed to prevent one case 
for each immunization strategy for the time period 2011–2060. All of the numbers, apart from the number of people needed 
to vaccinate (NNV), are in the thousands. Averages across 200 simulation runs. 
Strategy Duration of Pro-
tection 
# of Doses Cases Cases Prevented NNV 
EPI@12m 10 years 42,034 86.36 174.39 241 
EPI@5y 10 years 33,878 87.62 173.13 196 
EPI@10y 10 years 30,024 87.17 173.58 173 
Switch 10 years 39,961 77.34 183.41 218 
Booster 10 years 63,882 54.09 206.66 309 
EPI@12m 20 years 42,034 0.65 260 162 
EPI@5y 20 years 33,878 0.65 260 130 
EPI@10y 20 years 30,024 0.71 260 115 
Switch 20 years 39,961 0.65 260 154 
Booster 20 years 63,882 0.65 260 246 
EPI@12m 5 years 42,034 164.53 96.22 437 
EPI@5y 5 years 33,878 165.41 95.34 355 
EPI@10y 5 years 30,024 166.19 94.56 317 
Switch 5 years 39,961 158.59 102.16 391 
Booster 5 years 63,882 135.92 124.83 512 
EPI@12m Age-specific 42,034 148.6 112.3 374 
EPI@5y Age-specific 33,878 94.66 166.1 204 
EPI@10y Age-specific 30,024 96.28 164.47 183 
Switch Age-specific 39,961 95.56 165.19 242 
Booster Age-specific 63,882 72.09 188.66 339 
Vaccination programmes raise the average age of infection since vaccinated children 
are protected against disease. Routine immunization at 10 years (EPI@10y) is associated 
with the lowest median age of infection as it results in a large number of unprotected 
children at a very young age leading to a large number of cases in the under 10-year-olds 
(Figure 4). 




Figure 4. Box plot showing the median, interquartile range, and full range of the total number of cases by age group from 
200 simulation runs aggregated over the time period 2010–2060. 
The strategy with the highest median age of infection is the routine immunization 
targeting children on their first birthday, with or without a booster dose when they turn 
5 years of age. Anyone can develop invasive meningococcal disease, but rates of disease 
are higher in children under the age of 5 years [13]. However, carriage prevalence is higher 
in individuals aged 5–19 years [14]. Routine immunization of 1-year-old children leads to 
waning of vaccine protection by the teenage years, when there is still heightened risk of 
meningitis. A booster dose extends the protection until the individuals age into a lower 
risk age group, which in turn results in a decreased transmission.  
4. Discussion 
At the time of developing our previous model, data on the duration of vaccine-in-
duced protection was limited. We based our assumption of an average of 10 years dura-
tion of protection on findings from unpublished trials and expert opinion. The initial mass 
campaigns in the countries of the meningitis belt started taking place in 2010, but vaccina-
tion in children under the age of 12 months did not start before 2016. Here, we update our 
previous model to take into account findings from two recent studies, suggesting that 
protection lasts longer in individuals receiving MenAfriVac after the age of two years 
[6,7]. We used this updated model to assess the impact of a set of new vaccination strate-
gies and compared them to the current strategy followed by African countries, since 2015. 
Assuming that the duration of protection is at most 10 years, model results suggest 
that meningococcal disease cannot be eliminated within the first 50 years after the initial 
vaccination by the current or new strategies explored. On the contrary, provided that high 
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antibody levels persist for an average of 20 years, all strategies, including the current, re-
sult in a possible elimination of NmA cases since there are no predicted cases until at least 
2060. 
As a long-term strategy, in the absence of any catch-up campaigns, routine vaccina-
tion of 10 year olds would lead to the smallest average number of cases. However, includ-
ing the campaigns, in the case of determining which strategy leads to the least number of 
cases, assuming that the duration of protection is the same across all ages, no single-dose 
strategy is superior to the rest as there was considerable overlap in the results. This is due 
to the mini catch-up campaign, which is part of only the current strategy (EPI@12m) and 
not the other two (EPI@5y and EPI@10y). The main difference in the results comparing the 
strategies is in the age distribution of cases. Reductions in the number of cases in one age 
group results in a rise of cases in another age group. Routine vaccination at 12 months 
offers better protection in young children, whereas vaccination at older ages reduces dis-
ease burden in adolescents and young adults. The risk of developing at least one major 
sequelae after meningococcal meningitis is higher in children under the age of 5 years [15]. 
In this study, we do not calculate Disability Adjusted Life Years (DALYs), where an age-
specific weight may be appropriate. Assuming that vaccine protection is short-lived in 
children under the age of 5 years, the model suggests that it would be wiser to change the 
target age of routine immunization from 12 months to 5 years provided that coverage is 
at least 50%.  
Routine immunization at 10 years of age (EPI@10y) is consistently the most effective 
strategy across all different assumptions about the duration of vaccine protection in terms 
of the number of people needed to vaccinate (NNV). This is due to the small number of 
doses administered, calculated based on Chad’s population demography. The high an-
nual growth rate of the country results in a triangle-shaped age distribution with the num-
ber of individuals declining with age. The strategy associated with the highest NNV is the 
strategy with the additional booster dose since the number of doses is almost double that 
of the rest of the strategies. NNV is widely used in the scientific literature. The nature of 
the disease (endemic, epidemic, high/low 𝑹𝟎) as well as the way NNV is calculated can 
produce biased results [12] and, thus, caution should be taken when interpreting results 
or comparing NNVs with other diseases in the scientific literature. However, the highest 
NNV value of 485 produced by the simulations for the Booster strategy is far superior to 
NNV 2800-3700 estimated by Trotter et al. [16] when evaluating the response thresholds 
for reactive vaccination campaigns. 
This is the first model to explore the potential benefits of targeting schoolchildren for 
routine immunization with MenAfriVac. As in all mathematical models, there is uncer-
tainty around the model structure and certain key model parameters. The results from 
this work were generated using demographic data from Chad, a country lying entirely in 
the meningitis belt and which suffered from epidemics every 8 to 12 years before the in-
troduction of MenAfriVac in 2011 [9]. The same structure is used to model different coun-
tries across the belt; here, we chose Chad as a typical example, but given that country-
specific demography is not substantially different, we believe the results are more broadly 
generalisable to other meningitis belt countries. A number of key parameters, such as the 
transmission rate and the duration of natural immunity remain unknown; therefore, were 
kept the same as in the original study, allowing for a more direct comparison. Mixing 
parameters are also important in age-structured models. The carriage prevalence pro-
duced by our model is consistent with contact studies in Africa, in which the highest in-
tensity of contacts is observed in 5–15 year olds [17].  
We used several metrics to compare the different strategies qualitatively and quanti-
tatively. None of the strategies explored in this work is superior in all respects. This is 
especially true when vaccine induced protection is the same regardless of the age at vac-
cination. Immunising infants (EPI@12m) offers protection to young children and raise the 
median age of infection. However, the NNV to prevent one case is higher than the NNV 
to prevent one case when EPI targets 10-year-olds (EPI@10y). Leaving children up to the 
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age of 10 years unprotected, however, results in more cases in younger ages and less in 
older age groups. The Booster strategy may result in the least number of cases but it is the 
most costly intervention since it needs two doses and therefore we assume approximately 
double the cost of the others. A possible change in the current immunization schedule 
would have to be based in the prioritization of all the above factors.  
The uncertainty around the assumptions regarding the duration of protection was 
also explored in another mathematical model forecasting the impact of MenAfriVac vac-
cination by Jackson et al. [18]. In their study, they mainly focused on updating and vali-
dating their previous model in light of newly data [19]. In contrast to our work, Jackson 
et al. assumed that routine vaccination solely targets 9 months old children. They also 
explored the benefits of adding a booster dose at 10 years of age in a sensitivity analysis. 
Despite their structural differences, both models highlight the critical need for a long-term 
immunization strategy to sustain low levels of infection as well as the importance of con-
tinuous updating of models when new data become available. 
Since the start of immunization with MenAfriVac, there has been an increased dis-
ease incidence caused by serogroups other than serogroup A. A new pentavalent vaccine 
is being currently developed with the expectation of licensure by end of 2022 [20]. In order 
to estimate the impact of introducing this new pentavalent vaccine in an already vac-
cinated population, a more robust study, including a multi-serogroup model, should be 
performed. This will involve a number of new unknown parameters and further increase 
the complexity of the model structure. Yaesoubi et al. [21] developed a transmission dy-
namic model to investigate the cost-effectiveness of alternative vaccination strategies us-
ing the novel multivalent vaccine. They concluded that the inclusion of a catch-up cam-
paign with the novel vaccine would be a cost-effective way to further reduce the menin-
gococcal disease burden.  
Despite the limitations of this work, and the uncertainty surrounding the introduc-
tion of the pentavalent vaccine in the countries of the African meningitis belt, this analysis 
and the conclusions drawn can be used in the future by policymakers to understand the 
importance of the duration of vaccine protection and support decision making around 
vaccine scheduling, such as a shift to routine immunization at an older age or the addition 
of a booster dose. This change can either be the addition of a booster dose at a later age or 
simply the age of the primary dose. The aim of this study is to identify the optimal way to 
maintain the success of MenAfriVac in reducing the number of MenA cases in the long-
term. Additional work on the feasibility and cost-effectiveness of policy changes is also 
essential. In the future, with the advent and rollout of affordable multivalent vaccines, 
protection against NmA and other serogroups will be enhanced.  
5. Conclusions 
Models can be useful in investigating a range of assumptions and a variety of vaccine 
strategies. Further empirical studies of the duration of protection (or the duration of the 
immune response) following MenAfriVac will help to decrease uncertainty about the op-
timal vaccination policy.  
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Appendix A 
Table A1. List of the model compartments and their definitions. 
Compartment Name Definition 
S Susceptible individuals not vaccinated 
C Carriers of NmA not vaccinated 
I Individuals with invasive disease not vaccinated 
R Immune after colonization or disease not vaccinated 
SE Susceptible individuals vaccinated before the age of 5 years  
CE Carriers of NmA vaccinated before the age of 5 years 
IE Diseased individuals vaccinated before the age of 5 years 
RE Immune after colonization or disease vaccinated before the 
age of 5 years 
SV Susceptible individuals vaccinated after the age of 5 years 
CV Carriers of NmA vaccinated after the age of 5 years 
IV Diseased individuals vaccinated after the age of 5 years 
RV 
Immune after colonization or disease vaccinated after the 
age of 5 years 
People are born in the susceptible compartment (S). Children vaccinated up to the 
age of 5 years are transferred to the SE, CE, IE, and RE compartments while individuals 
who are targeted at 5 years or older are moved to the SV, CV, IV, RV compartments ac-
cordingly. For example, during the initial mass campaigns, children in the age groups 1–
2 years, 2–3 years, 3–4 years, and 4–5 years are transferred to the early vaccination com-
partments (SE, CE, IE, RE) while individuals between 5 and 29 years of age are moved to 
the vaccinated compartments SV, CV, IV, and RV. Note that there is no movement to the 
IE or IV compartments upon vaccination as we assume that individuals with meningitis 
do not receive a vaccine dose. Individuals in the vaccinated states (SE, SV, CE, CV, IE, IV, 
RE, RV) revert to the equivalent unvaccinated S, C, I, R states at the age-specific rates 𝐰𝟏 
and 𝐰𝟐, depending on the strategy implemented (Figure A1). When duration of protection 
is the same for all ages, then 𝐰𝟏 = 𝐰𝟐. 
With the addition of the extra compartments, the force of infection for age group j 
becomes  
𝝀𝒋 = 𝜽 𝜷(𝒛𝒋, 𝒛𝒌)(𝑰𝒌 + 𝑪𝒌 + 𝑰𝑽𝒌 + 𝑪𝑽𝒌 + 𝑰𝑬𝒌 + 𝑪𝑬𝒌)𝟏𝟎𝟎𝒌 𝟏  (A1)
where θ is the stochastic term, which changes annually, and was previously described [4] 
and 𝜷(𝒛𝒋, 𝒛𝒌) is the transmission rate between age groups j and k. 




Figure A1. Flow diagram of the model with vaccination. Susceptible individuals become carriers with age and time de-
pendent force of infection (λ(z,t)), which is reduced by the vaccine efficacy against carriage (δ) for vaccinated people. 
Similarly, the age and time dependent rate at which carriers develop disease (a(z,t)) is reduced by the vaccine efficacy 
against disease (ξ). Carriers and diseased individuals recover at a rate α and ρ, respectively. Temporary immunity wanes 
at a rate φ, while vaccine induced protection wanes at a rate 𝑤  for children vaccinated before the age of 5 years and 𝑤  
for people vaccinated after their 5th birthday. People die at an age-specific natural mortality rate not shown here. 
Appendix B 
Table A2. Numerical results for the different vaccination scenarios for the time period 2010–2060. Duration of protection 
is 10 years and vaccine uptake for children routinely immunized over the age of 12 months is assumed to be 80%. Each 
value presented is the mean and 95% confidence interval is given inside the brackets. 
Outcome No vaccination EPI@12m EPI@5y EPI@10y Switch Booster 
Total number of 
cases (in thou-
sands) 
260.7 (258–263.4) 86.3 (84.6–88.1) 87.6 (85.8–89.3) 87.1 (85.1–89.2) 77.3 (75.1–79.5) 54.1 (52.5–55.6) 
Cases averted 




175.5) 173.5 (171.1–176) 183.4 (181–185.8) 206.6 (204.3–209) 
% of cases 
averted 
- 66.8 (66.2–67.4) 66.4 (65.8–67) 66.6 (65.9–67.2) 70.4 (69.7–71.1) 79.3 (78.7–79.8) 
Year of resur-
gence 
- 2032 2030 2027 2034 2031 
Total number of 
doses given (in 
millions) 
- 42.03 33.87 30.02 39.96 63.88 
NNV - 241 196 173 218 309 
Table A3. Summary statistics showing the year disease incidence exceeds the threshold of 1 case per 100,000 population 
from 200 simulation runs for a range of values for the duration of protection. The scenario simulated to generate these 
results is the EPI@12m. 
Duration of Protection 11 Years 12 Years 13 Years 14 Years 15 Years 16 Years  17 Years 18 Years * 
Minimum 2033 2035 2037 2040 2044 2047 2056 - 
1st Quartile 2038 2041 2044 2048 2053 2053 2057 - 
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Median 2040 2043 2047 2051 2056 2057 2058 - 
Mean 2040 2043 2047 2051 2055 2056 2058 - 
3rd Quartile 2042 2045 2049 2054 2058 2059 2058 - 
Maximum 2049 2054 2059 2060 2060 2060 2060 - 
# of runs leading to elimina-
tion 
0 0 0 3 58 139 195 200 
% of runs leading to elimi-
nation 0 0 0 1.5 29 69.5 97.5 100 
* All 200 simulations resulted in elimination. 
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